Ursodeoxycholic acid-containing agent for treating or preventing presbyopia

Patent metadata

Field	Value
Publication number	US-2022072012-A1
Application number	US-201917414285-A
Country	US
Kind code	A1
Filing date	Dec 17, 2019
Priority date	Dec 18, 2018
Publication date	Mar 10, 2022
Grant date	—

Abstract

The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

First claim

1 . (canceled)

2 . (canceled)

3 . (canceled)

4 . (canceled)

5 . (canceled)

6 . (canceled)

7 . (canceled)

8 . (canceled)

9 . (canceled)

10 . (canceled)

11 . (canceled)

12 . (canceled)

13 . A method for treating or preventing presbyopia, comprising administering to a subject in need thereof an effective amount of ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

14 . The method according to claim 13 , wherein the ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof, is administered ophthalmically.

15 . The method according to claim 13 , wherein the ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof, is administered as an eye drop or an eye ointment.

16 . The method according to claim 15 , wherein the amount of ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof, comprised in the eye drop or the eye ointment is 0.00001 to 10% (w/v).

17 . The method according to claim 13 , wherein the ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof, is selected from ursodeoxycholic acid, tauroursodeoxycholic acid, glycoursodeoxycholic acid, ursodeoxycholic acid methyl ester, ursodeoxycholic acid ethyl ester, ursodeoxycholic acid n-propyl ester, ursodeoxycholic acid isopropyl ester, ursodeoxycholic acid n-butyl ester, ursodeoxycholic acid isobutyl ester, ursodeoxycholic acid sec-butyl ester, ursodeoxycholic acid tent-butyl ester, ursodeoxycholic acid n-pentyl ester, ursodeoxycholic acid n-hexyl ester, or a pharmaceutically acceptable salt thereof.

18 . The method according to claim 13 , wherein the ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof, is selected from ursodeoxycholic acid, tauroursodeoxycholic acid, glycoursodeoxycholic acid, ursodeoxycholic acid methyl ester, ursodeoxycholic acid ethyl ester, ursodeoxycholic acid n-propyl ester, ursodeoxycholic acid isopropyl ester, or a pharmaceutically acceptable salt thereof.

19 . The method according to claim 13 , wherein the ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof, is ursodeoxycholic acid or a sodium salt thereof.

20 . The method according to claim 15 , wherein the eye drop or the eye ointment comprises water, and an additive selected from ethyl pyruvate, sodium dihydrogenphosphate monohydrate, disodium hydrogenphosphate, hydroxypropyl methylcellulose, NaCl, or a mixture thereof.

21 . A method for treating or preventing an eye disease accompanied by a decrease in lens elasticity, comprising administering to a subject in need thereof an effective amount of ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

22 . A method for treating or preventing an eye disease accompanied by a decrease in accommodative function of the eye, comprising administering to a subject in need thereof an effective amount of ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

Assignees

• Santen Pharmaceutical Co Ltd

Inventors

• Kato Masatomo
• Oda Tomoko
• Kido Kazutaka

Classifications

• A61K47/02

  Inorganic compounds · CPC title

• A61K9/10

  Dispersions; Emulsions · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61P27/10

  for accommodation disorders, e.g. myopia · CPC title